New Protective Agents for Bone Marrow in Cancer Therapy

References

• Barron E SG. Thiol groups of biological importance. Adv Enzymol 1946; 11: 201–266
   Google Scholar
• Patt H, Tyree E B, Staube R L, et al. Cysteine protection against x-irradiation. Science 1949; 110: 213–214
   PubMed Web of Science ®Google Scholar
• Weiss J F, Simic M G. Introduction: perspectives in radioprotection. Pharmac Ther 1988; 39: 1–2
   PubMed Web of Science ®Google Scholar
• Davidson D E, Grenan M M, Sweeney T R. Biological characteristics of some improved radioprotectors. Radiation Sensitizers., L Brady. Masson, New York 1980; 309–320
   Google Scholar
• Chapman J D, Reuvers A P, Borsa J, et al. Chemical radioprotection and radiosensitization of mammalian cells growing in vitro. Radiat Res 1973; 56: 291–306
   PubMed Web of Science ®Google Scholar
• Willson R L. Free radical repair mechanisms and the interactions of glutathione and vitamin C and E. Radioprotectors and Anticarcinogens., O F Nygaard, M G Simic. Academic Press, New York 1983; 1–23
   Google Scholar
• Grdina D J, Sigdestad C P. Radiation protectors: The unexpected benefits. Drug Metabol Rev 1989; 20(1)1342
   Web of Science ®Google Scholar
• Yuhas J M. Biological factors affecting the radioprotective efficiency of S-2-[3-aminopropylamo]ethylphosphorothioic acid (WR-2721). LD50(30) doses. Radiat Res 1970; 44: 621–628
   PubMedGoogle Scholar
• Brown D Q, Pittock J W, Rubinstein J S. Early results of the screening program for radioprotectors. Int J Radiat Oncol Biol Phys 1982; 8: 565–570
   PubMed Web of Science ®Google Scholar
• Yuhas J M. Differential protection of normal and malignant tissues against the cytotoxic effects of mechlorethamine. Cancer Treat Rep 1979; 63: 971–976
   PubMedGoogle Scholar
• Wasserman T H, Phillips T L, Roses G, et al. Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFU's by WR-2721. Cancer Clin Trials 1981; 4: 3–6
   PubMedGoogle Scholar
• Valeriote F, Tolen S. Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res 1982; 42: 4330–4331
   PubMed Web of Science ®Google Scholar
• Millar J L, McElwain T J, Clutterbuck R D, et al. The modification of melphalan toxicity in tumor bearing mice by S-2-(3-aminopropylamino)ethylphosphoro-thioic acid (WR-2721). Am J Clin Oncol (CCT) 1982; 5: 321–328
   PubMed Web of Science ®Google Scholar
• Green D C, Talebian A, Schein P S. Evaluation of the chemoprotective effects of WR-2721 and WR-151327 in mice. Proc Am Assoc Cancer Res 1989; 30: 1871
   Google Scholar
• Yuhas J M, Storer J B. Differential chemoprotection of normal and malignant tissues. J Natl Cancer Inst 1969; 42: 331–335
   PubMed Web of Science ®Google Scholar
• Yuhas J M, Spellman J M, Culo F. The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clin Trials 1980; 3: 211–216
   PubMedGoogle Scholar
• Yuhas J M. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)ethylphos-phorothioic acid. Cancer Res 1980; 40: 1519–1524
   PubMed Web of Science ®Google Scholar
• Harris J W, Phillips T L. Radiobiological and biochemical studies of thiophosphate radioprotective compounds related to cystamine. Radiat Res 1971; 46: 362–379
   PubMed Web of Science ®Google Scholar
• Shaw L M, Turrisi A T, Glover D J, et al. Human pharmacokinetics ofWR-2721. Int J Radiat Oncol Biol Phys 1986; 12: 1501–1504
   PubMed Web of Science ®Google Scholar
• Calabro-Jones P M, Fahey R C, Soluk G D, et al. Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79–171 cells incubated in medium containing WR-2721. Int J Radiat Biol 1985; 47: 23–27
   Web of Science ®Google Scholar
• Meagher R C, Rothman S A, Paul P, et al. Purging of small cell lung cancer cells from human bone marrow using ethiofos (WR-2721) and light-activated merocyanine 540 phototreatment. Cancer Res 1989; 49: 3637–3641
   PubMed Web of Science ®Google Scholar
• Grdina D J, Nagy B, Sigdestad C P. Radioprotectors in treatment therapy to reduce risk in secondary tumor induction. Pharmac Ther 1988; 39: 21–25
   PubMed Web of Science ®Google Scholar
• Riklis E, Kol R, Green M, et al. Increased radioprotection attained by DNA repair enhancement. Pharmac Ther 1988; 39: 311–322
   PubMed Web of Science ®Google Scholar
• Kligerman M M, Shaw M T, Slavik M, et al. Phase I clinical studies with WR-2721. Cancer Clin Trials 1980; 3: 217–221
   PubMedGoogle Scholar
• Turrisi A T, Glover D J, Hurwitz S, et al. Final report on the Phase I trial of single dose WR-2721 (S-2-(3-aminopropylamine)-ethyl phosphorothioic acid). Cancer Treat Rep 1986; 70: 1389–1393
   PubMedGoogle Scholar
• Glover D, Fox K R, Weiler C, et al. Clinical trials of WR-2721 prior to alkylating agent chemotherapy and radiotherapy. Pharmac Ther 1988; 39: 3–7
   PubMed Web of Science ®Google Scholar
• Kligerman M M, Glover D J, Turrisi A T, et al. Toxicity of WR-2721 administered in single and multiple doses. Int J Radiat Oncol Biol Phys 1984; 10(9)1773–6
   PubMed Web of Science ®Google Scholar
• Glover D J, Glick J H, Weiler C, et al. WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase III trial. J Clin Oncol 1986; 4: 584–588
   PubMed Web of Science ®Google Scholar
• Yuhas J M, Culo F. Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum(II) by WR-2721 without altering its antitumor properties. Cancer Treat Rep 1980; 64: 57–64
   PubMedGoogle Scholar
• Yuhas J M, Spellman S W, Jordan M C. Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclosphosphamide. Br J Cancer 1980; 42: 574–585
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Sugahara T. Clinical experiences of chemical radiation protection in tumor radiotherapy in Japan. Radiation Sensitizers., L Brady. Masson, New York 1980; 421–425
   Google Scholar
• Takahashi I, Nagai T, Miyaishi K, et al. Clinical study of the radioprotective effects of amifostine (YM-08310, WR-2721) on chronic radiation injury. Int J Radiat Oncol Biol Phys 1986; 12: 935–938
   PubMed Web of Science ®Google Scholar
• Constine L S, Zagars G, Rubin P, et al. Protection by WR-2721 of human bone marrow function following irradiation. Int J Radiat Oncol Biol Phys 1986; 12: 1505–1508
   PubMed Web of Science ®Google Scholar
• Glick J H, Glover D, Weiler C, et al. Phase I controlled trials of WR-2721 and cyclophosphamide. Int J Radiat Oncol Biol Phys 1984; 10: 1777–1780
   PubMed Web of Science ®Google Scholar
• Glover D, Glick J H, Weiler C, et al. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol 1987; 5: 574–578
   PubMed Web of Science ®Google Scholar
• Ainsworth J E. From endotoxins to newer immunomodulators: survival-promoting effects of microbial polysaccharide complexes in irradiated animals. Pharmac Ther 1988; 39: 223–241
   PubMed Web of Science ®Google Scholar
• Seifter E, Mendecki J, Holtzman S, et al. Role of vitamin A and beta-carotene in radiation protection: relation to antioxidant properties. Pharmac Ther 1988; 39: 357–365
   PubMed Web of Science ®Google Scholar
• Patchen M L, D'Alesandro M, Chirigos M A, et al. Radioprotection by biological response modifiers alone and in combination with WR-2721. Pharmac Ther 1988; 39: 247–254
   PubMed Web of Science ®Google Scholar
• Maisin J R, Topalova S, Kondi-Tamba A, et al. Radioprotection by polysaccharides. Pharmac Ther 1987; 39: 255–259
   Web of Science ®Google Scholar
• Thomas L. The physiological disturbances produced by endotoxins. Ann Rev Physiol 1954; 16: 467–490
   PubMed Web of Science ®Google Scholar
• Smith W W, Alderman I M, Gillespie R E. Increased survival in irradiated animals treated with bacterial endotoxins. Am J Physiol 1957; 191: 124–130
   PubMed Web of Science ®Google Scholar
• Behling U H. The radioprotective effect of bacterial endotoxin. Beneficial Effects of Endotoxins. Plenum Press, New York 1983; 127–148
   Google Scholar
• Burgaleta C, Golde D W. Effects of glucan on granulopoiesis and macrophage genesis in mice. Cancer Res 1977; 37: 1739–1742
   PubMed Web of Science ®Google Scholar
• Patchen M L, Lotzova E. Modulation of murine hemopoiesis by glucan. Exp Hematol 1980; 8: 409–422
   PubMed Web of Science ®Google Scholar
• Neta R. Role of cytokines in radioprotection. Pharmac Ther 1988; 39: 261–266
   PubMed Web of Science ®Google Scholar
• Walden T L, Jr., Patchen M L, Snyder S L. 16,16-Dimethl prostaglandin E increases survival in mice following irradiation. Radiat Res 1987; 109: 540–549
   Web of Science ®Google Scholar
• Walden T L, Jr., Kalinich J F. Radioprotection by leukotrienes: is there a receptor mechanism?. Pharmac Ther 1988; 39: 379–384
   PubMed Web of Science ®Google Scholar
• Aglietta M, Gavosto F. CSFS, from basic science to clinical trials. Bone Marrow Transplant 1989; 4: 16–18
   PubMed Web of Science ®Google Scholar
• Klingemann H G. Clinical applications of recombinant human colony-stimulating factors. Can Med Assoc J 1989; 140(2)137–142
   Web of Science ®Google Scholar
• Antman K S, Griffin J D, Elias A, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppresion. N Engl J Med 1988; 319: 593–598
   PubMed Web of Science ®Google Scholar
• Grdina D J, Nagy B, Hill C K, et al. The radioprotector WR-1065 reduced radiation-induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in V79 cells. Carcinogenesis 1985; 6: 929–931
   PubMed Web of Science ®Google Scholar
• Nagy B, Dale P J, Grdina D J. Protection against cis-diamminedichloroplatinum cytotoxicity and mutagenicity in V79 cells by 2-[(aminopropyl)amino] ethanethiol. Cancer Res 1986; 46: 1132–1135
   PubMed Web of Science ®Google Scholar
• Nagy B, Grdina D J. Protective effects of 2-[(aminopropyl)amino] ethanethiol against bleomycin and nitrogen mustard-induced mutagenicity in V79 cells. Int J Radiat Oncol Biol Phys 1986; 12: 1475–1478
   PubMed Web of Science ®Google Scholar
• Hill C K, Nagy B, Peraino C, et al. 2-[(aminopropyl)amino] ethanethiol (WR-1065) is anti-neoplastic and anti-mutagenic when given during 60Co gamma-ray irradiation. Carcinogenesis 1986; 7: 665–668
   PubMed Web of Science ®Google Scholar
• Grdina D J, Peraino C, Carnes B A, et al. Protective effect of S-2-(3-aminopropylamino)ethylphosphoro-thioic acid against induction of altered hepatocyte foci in rats treated once with gammaradiation within one day after birth. Cancer Res 1985; 45: 5379–5381
   PubMed Web of Science ®Google Scholar
• Milas L, Hunter N, Stephens C L, et al. Inhibition of radiation car-cinogenesis by S-2-(3-aminopropyl-amino)-ethylphosphorothioic acid. Cancer Res 1984; 44: 5567–5569
   PubMed Web of Science ®Google Scholar